Log in

Relevant bibliographies by topics / Cleopatra III / Journal articles

Journal articles on the topic 'Cleopatra III'

To see the other types of publications on this topic, follow the link: Cleopatra III.

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 47 journal articles for your research on the topic 'Cleopatra III.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Pearce, Sarah. "THE CLEOPATRAS AND THE JEWS." Transactions of the Royal Historical Society 27 (November 1, 2017): 29–64. http://dx.doi.org/10.1017/s0080440117000032.

Full text

Abstract:

ABSTRACTThis paper explores a variety of evidence for relations between Cleopatra VII, the last Ptolemaic ruler of Egypt, and her Jewish subjects. In the first part of the paper, the focus is on the profoundly negative portrait of the queen in the works of Josephus, with particular attention to Cleopatra's alleged antipathy to Alexandrian Jews in Josephus's Against Apion. Analysis of Josephus's evidence confirms, I argue, that his case against the queen does not stand up. The second part of the paper offers a detailed consideration of other evidence, epigraphic and literary, which, I suggest, confirms a picture of the queen as continuing the policy of her predecessors with regard to the Jews of the Ptolemaic kingdom, by participating in the long-established practice of extending royal support and protection to Jewish proseuchai (places of prayer). While the evidence does not permit definitive conclusions, it suggests that Cleopatra looked to particular Jewish groups – as to others – within Egypt for support and in this, followed a path taken by Cleopatra II and Cleopatra III. Finally, a few details in Plutarch's Life of Antony may also suggest the queen's political and personal alliances with individual Jews, in Egypt and Judea.

APA, Harvard, Vancouver, ISO, and other styles

2

Musgrave, Jonathan. "Dust and Damn'd Oblivion: A Study of Cremation in Ancient Greece." Annual of the British School at Athens 85 (November 1990): 271–99. http://dx.doi.org/10.1017/s0068245400015689.

Full text

Abstract:

In this paper – the revised text of a public lecture given in Athens on 23 February 1989 – the author reviews both the historical and anatomical evidence for identifying the occupants of the royal tombs at Vergina as: Tomb I: not known; Tomb II: Philip II and either Cleopatra or Meda; Tomb III: Alexander IV. The case for Philip III Arrhidaios and Eurydice in Tomb II is shown to be anthropologically weak. The paper also includes a catalogue of the human remains from Tomb II antechamber (Cleopatra or Meda) and Tomb III (Alexander IV). The arrival of cremation in Greece, and both Homeric and later Macedonian attitudes to the rite are also discussed. The general conclusion is that cremations are a valuable source of biological and archaeological information.

APA, Harvard, Vancouver, ISO, and other styles

3

Urruticoechea, Ander, Seock-Ah Im, Montserrat Munoz, Jose Baselga, Denise A. Yardley, Sarah Heeson, Sarah Jones, et al. "Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 1023. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1023.

Full text

Abstract:

1023 Background: T-DM1 was approved for pts with HER2+ MBC previously treated with trastuzumab (H) and a taxane based on the phase III EMILIA study. P in combination with H + docetaxel (T) later became the first-line standard of care for HER2+ MBC, but there are limited data on T-DM1 efficacy in pts who previously received P. We present exploratory efficacy results from pts treated with T-DM1 any time after P from 2 phase III studies: CLEOPATRA and PHEREXA. Methods: CLEOPATRA (NCT00567190) and PHEREXA (NCT01026142) are randomized, 2-arm trials evaluating P-based regimens for HER2+ MBC. CLEOPATRA studies H + T + P vs HT + placebo in pts with no prior anti-HER2 treatment (tx) or chemotherapy for MBC, while PHEREXA studies H + capecitabine (C) +/− P in pts who progressed during/after previous H tx for MBC. We assessed overall survival (OS) in an exploratory analysis of pts who either received or did not receive T-DM1 at any time after discontinuing study-assigned tx in CLEOPATRA or PHEREXA. Results: Of 408 pts who received HTP in CLEOPATRA and 228 pts who received HCP in PHEREXA, 32 and 43 pts received subsequent T-DM1, respectively (Table). Median duration of T-DM1 tx was 7.1 mo (range 0−44) and 4.2 mo (range 0−22), respectively, and median time from discontinuation of P to start of T-DM1 was 3.5 mo (range 1−47) and 10.6 mo (range 1−28). Conclusions: Although data are limited in these exploratory analyses, our results provide additional evidence of T-DM1 clinical activity in pts with HER2+ MBC who progressed on prior P + H, a finding with real-world implications. Clinical trial information: NCT00567190, NCT01026142. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

4

Lenzo, Giuseppina. "A Xoite Stela of Ptolemy VIII Euergetes II with Cleopatra II and Cleopatra III (British Museum EA 612)*." Journal of Egyptian Archaeology 101, no. 1 (January 2015): 217–37. http://dx.doi.org/10.1177/030751331510100111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Henning, Peter. "Metastasiertes HER2-positives -Mamma-Karzinom: Erstlinientherapie mit Pertuzumab." Onkologische Welt 03, no. 04 (2012): 172. http://dx.doi.org/10.1055/s-0038-1630202.

Full text

Abstract:

Die Phase-III-Studie CLEOPATRA (Clinical Evaluation Of Pertuzumab And TRAstzumab) zeigt eine statistisch signifikante und klinisch relevante Verbesserung des progressionsfreien überlebens durch Pertuzumab bei HER2 positivem metastasiertem Mamma- Karzinom in der Erstlinientherapie (1), so das Fazit von Prof. Andreas Schneeweiss, Leiter der Sektion Gynäkologische Onkologie am Nationalen Centrum für Tumorerkrankungen, Heidelberg.

APA, Harvard, Vancouver, ISO, and other styles

6

Xu, Binghe, Wei Li, Qingyuan Zhang, Shao Zhimin, Wang Xiao Jia, Huiping Li, Tao Sun, et al. "A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1026. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1026.

Full text

Abstract:

1026 Background: In CLEOPATRA (NCT00567190), adding P to H + D significantly improved progression-free and overall survival (PFS/OS) v Pla + H + D in patients (pts) with previously untreated HER2-positive LR/MBC. PUFFIN (NCT02896855) is a China bridging study; the objective being to assess consistency of efficacy with CLEOPATRA. Methods: Pts with previously untreated HER2-positive LR/MBC were randomized 1:1 to P + H + D or Pla + H + D, stratified by visceral v non-visceral disease and hormone receptor status. The primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR in pts with measurable baseline disease), OS, and safety. The target sample size (240) was determined based on the consistency threshold for PFS, defined as hazard ratio (HR) < 0.81, which maintains ≥ 50% of the risk reduction determined in CLEOPATRA (HR 0.62). Results: Two hundred forty-three pts were randomized. Baseline/disease characteristics and prior therapies were generally balanced between arms. For PFS, the HR was 0.69 (95% CI 0.49, 0.99) in the ITT population. No cases of heart failure or symptomatic left ventricular ejection fraction decline were reported. Efficacy/safety are shown in the table. Conclusions: PUFFIN met its primary endpoint. Overall, efficacy data were consistent with CLEOPATRA (ITT population and Asian subgroup). Safety was also consistent and in line with the known P safety profile, with no new or unexpected signals reported. PUFFIN adds to the totality of data with P in previously untreated HER2-positive LR/MBC, and supports the favorable benefit–risk profile of P in Chinese pts. Clinical trial information: NCT02896855. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

7

Gómez Lara, Manuel José. "«'O, Never was there queen/ So mightly Betray'd' (I,iii,24-5): Locura de amor en "Antony and Cleopatra"»." Philologia Hispalensis 1, no. 2 (1987): 17–28. http://dx.doi.org/10.12795/ph.1987.v02.i01.02.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ciruelos Gil, Eva Maria, Adam Brufsky, Young-Hyuck Im, Sung-Bae Kim, Emma Clark, Adam Knott, Graham Ross, and David Miles. "Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 600. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.600.

Full text

Abstract:

600 Background: CLEOPATRA is a global phase III trial of P + T + D vs placebo + T + D in HER2-positive 1L MBC. Results showed a significant improvement in PFS (Baselga NEJM 2012) and OS (Swain SABCS 2012) favoring P + T + D. CLEOPATRA started recruitment in 2008 soon after the approval of T in the adjuvant setting in 2006 and mandated a disease-free interval (DFI) of ≥12 mos from the end of adjuvant therapy to MBC diagnosis. Due to this, a low proportion of pts with prior T exposure was included. Here we present the efficacy and safety of 1L P + T + D in the subset of pts in CLEOPATRA with prior T exposure. Methods: Pts received P + T + D or placebo + T + D, had a DFI ≥12 mos, baseline left ventricular ejection fraction (LVEF) ≥50% and no LVEF decline to <50% during/after prior T therapy. Exploratory analyses of PFS and OS in pts with (neo)adjuvant therapy with or without T were conducted. Results: Of the study population, 47% had received (neo)adjuvant therapy and 11% had received (neo)adjuvant T; 82% of the prior T group came from Europe or North America. A univariate Cox regression analysis did not identify prior T therapy as a statistically significant risk factor for developing left ventricular systolic dysfunction (LVSD). However, due to the low number of LVSD events overall, this analysis has limited sensitivity. Conclusions: Data from CLEOPATRA show that pts with HER2-positive 1L MBC who have received prior T (DFI ≥12 mos) derive the same magnitude of benefit from the combination of P + T + D when compared with the whole study population or those who are T-naïve. This is in agreement with prior evidence of the activity of P + T in pts pretreated with T (Baselga JCO 2010). Efficacy and safety of P-T-based therapy is being explored in the PERUSE and PHEREXA trials, in a pt population with wider exposure to prior T and a shorter DFI, which may better represent current clinical practice. Clinical trial information: NCT00567190. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

9

Baselga, José, and Sandra M. Swain. "CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer." Clinical Breast Cancer 10, no. 6 (December 2010): 489–91. http://dx.doi.org/10.3816/cbc.2010.n.065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ali, Ali. "THE COLUMN OF CLEOPATRA III AND PTOLEMY IX FROM KOM OMBO IN THE GEM (45481)." Shedet 7, no. 7 (December 31, 2020): 1–25. http://dx.doi.org/10.21608/shedet.2021.32773.1020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Baselga, José, Javier Cortés, Seock-Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, and Sandra M. Swain. "Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer." Journal of Clinical Oncology 32, no. 33 (November 20, 2014): 3753–61. http://dx.doi.org/10.1200/jco.2013.54.5384.

Full text

Abstract:

PurposeTo explore the prognostic and/or predictive value of human epidermal growth factor receptor 2 (HER2) pathway–related biomarkers in the phase III CLEOPATRA study of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel as first-line treatment for patients with HER2-positive metastatic breast cancer.Patients and MethodsMandatory tumor and serum samples were collected (N = 808; 58% to 99.8% were assessable), and amphiregulin, betacellulin, epidermal growth factor (EGF), transforming growth factor alpha, EGF receptor, HER2, HER3, insulin-like growth factor 1 receptor, PTEN, phosphorylated AKT, PIK3CA, CMYC, serum HER2 extracellular domain (sHER2), and FCγR were assessed using appropriate assays. Two types of correlations were investigated using univariable Cox regression: predictive effects (qualitative association of biomarkers with pertuzumab progression-free survival [PFS] benefit) and prognostic effects independent of treatment arm (relationship of each biomarker to clinical outcome in both arms pooled).ResultsPertuzumab consistently showed a PFS benefit, independent of biomarker subgroups (hazard ratio < 1.0), including estrogen receptor–negative and –positive subgroups. High HER2 protein, high HER2 and HER3 mRNA levels, wild-type PIK3CA, and low sHER2 showed a significantly better prognosis (P < .05). PIK3CA showed the greatest prognostic effect, with longer median PFS for patients whose tumors expressed wild-type versus mutated PIK3CA in both the control (13.8 v 8.6 months) and pertuzumab groups (21.8 v 12.5 months).ConclusionThrough comprehensive prospective analyses, CLEOPATRA biomarker data demonstrate that HER2 is the only marker suited for patient selection for the trastuzumab plus pertuzumab–based regimen in HER2-positive metastatic breast cancer. HER2, HER3, and PIK3CA were relevant prognostic factors.

APA, Harvard, Vancouver, ISO, and other styles

12

Ewer, Michael, José Baselga, Emma Clark, Mark Benyunes, Graham Ross, and Sandra M. Swain. "Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 533. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.533.

Full text

Abstract:

533^ Background: Addition of trastuzumab (T) to chemotherapy has transformed outcomes in pts with HER2-positive breast cancer. In pts who had received anthracyclines (A), T has been associated with cardiac dysfunction. Monitoring cardiac tolerability of anticancer drugs is important, including that of a new regimen combining T with a second anti-HER2 antibody that inhibits HER2 dimerization, pertuzumab (P). In CLEOPATRA, efficacy and safety of P+T+docetaxel (D) were studied in HER2-positive 1st-line MBC (Baselga 2012). Methods: CLEOPATRA, a randomized, double-blind, placebo-controlled, ph III trial, enrolled 808 pts; 804 were included in the safety population. A baseline (BL) LVEF ≥50%, no history of congestive heart failure, and no LVEF decline to <50% during/after prior T were required. Treatment was administered q3w until disease progression or unmanageable toxicity (P/placebo [Pla]: 840 mg, followed by 420 mg; T: 8 mg/kg, followed by 6 mg/kg; D [≥6 cycles recommended]: 75 mg/m2, escalating to 100 mg/m2 if tolerated). LVEF was assessed by ECHO or MUGA at BL, every 9 wks during treatment, at discontinuation, and up to 3 yrs thereafter. Adverse events (AE) were monitored continuously and graded according to NCI-CTCAE v3.0. Results: The incidence of any cardiac disorder (grade ≥1) as assessed by the investigators was similar with Pla+T+D (16.4%) and P+T+D (14.5%). LVSD (grade ≥1) was the most frequent cardiac AE and more common with Pla+T+D. At the time of data cutoff for this analysis, 8/11 symptomatic LVSD events had resolved; none fatal. All pts who developed symptomatic LVSD had ≥1 potential cardiac risk factor (prior A, prior T, radiation, smoking, diabetes, hypertension, other). Compared to the overall pt population, only prior A and radiation were higher in pts who developed symptomatic LVSD. Conclusions: CLEOPATRA provides evidence that P+T+D does not increase overall cardiac disorders, specifically symptomatic LVSD, compared to Pla+T+D. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

13

Clegg, Cyndia. "The Undiscovered Countries: Shakespeare and the Afterlife." Religions 10, no. 3 (March 10, 2019): 174. http://dx.doi.org/10.3390/rel10030174.

Full text

Abstract:

The multiple uses of religion in Shakespeare’s plays seem to counter each other at every turn. In one respect, though, I have found a surprising consistency. Moments when Shakespeare’s drama imagines the afterlife are moments that lend significant insights into the play’s action or characterization, even though the image of one undiscovered country may differ drastically from another. Across the canon, the afterlife may appear as a place of religious judgment, as in Othello, Hamlet, Merchant of Venice; as a classical Elysium or Hades where the spirit or shadow removes elsewhere (Antony and Cleopatra, Titus Andronicus); as Abraham’s Bosom—a place of rest between death and the Last Judgment (Henry V, Richard III, Hamlet); or an unidentifiable life to come (Macbeth, King Lear).

APA, Harvard, Vancouver, ISO, and other styles

14

Miles, D., Y. H. Im, A. Fung, B. Yoo, A. Knott, S. Heeson, M. S. Beattie, and S. M. Swain. "Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial." Annals of Oncology 28, no. 11 (November 2017): 2761–67. http://dx.doi.org/10.1093/annonc/mdx406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Cortes, Javier, José Baselga, Young-Hyuck Im, Graham Ross, Emma Clark, Adam Knott, and Sandra M. Swain. "Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 598. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.598.

Full text

Abstract:

598^ Background: CLEOPATRA compared the efficacy and safety of the HER2 dimerization inhibitor pertuzumab (P) plus trastuzumab (T) and docetaxel (D) with placebo (Pla)+T+D in HER2-positive 1st-line MBC. Pts in both arms received a median of 8 cycles of D; Pla/P+T was continued until progressive disease (PD). The safety profile in both arms was similar with a substantial decrease in adverse events (AEs) once chemotherapy finished. The independently assessed progression-free survival was significantly improved with P+T+D compared with Pla+T+D; objective response and duration of response were also improved with P+T+D (Baselga NEJM 2012). Here we report health-related quality of life (HRQoL) data from CLEOPATRA. Methods: Time to deterioration of HRQoL was evaluated using the FACT-B questionnaire and defined as decrease from baseline (BL) of ≥5 points in the TOI-PFB subscale score. Female pts completed questionnaires every 3rd cycle of therapy within 3 days before each tumor assessment until independently determined PD. An exploratory analysis investigated time to deterioration in breast cancer symptoms and functions. Results: 56.7% (Pla+T+D) and 59.5% (P+T+D) of pts experienced deterioration of HRQoL during the study based on TOI-PFB. The median time to deterioration was 18.3 vs 18.4 wks (~6 cycles) (HR 0.97; P = .7161). At Cycle 6, the mean reduction in TOI-PFB score from BL was –3.5 (Pla+T+D) vs –3.0 (P+T+D). At subsequent cycles, when most pts had discontinued D, mean reductions were smaller, suggesting that after an early decline patients’ scores improved slightly. Overall, mean changes were small in both arms. Compliance with completion of the FACT-B questionnaire was ≥75% beyond the 1st year in both arms. An exploratory analysis suggested that time to deterioration in BCS score, which measures symptoms and issues relevant in breast cancer, was delayed with P+T+D (18.3 vs 26.7 wks; HR 0.77; P = .0061). Conclusions: Combining P with T+D appears to have no detrimental effect on HRQoL. Results suggest that P+T+D is associated with a substantial delay in the time to deterioration in BCS score as would be expected given the improved efficacy and the low incidence of AEs once D is discontinued.

APA, Harvard, Vancouver, ISO, and other styles

16

Bartsch, Rupert, and Elisabeth Bergen. "ASCO 2019: highlights in HER2-positive metastatic breast cancer." memo - Magazine of European Medical Oncology 12, no. 4 (November 12, 2019): 308–11. http://dx.doi.org/10.1007/s12254-019-00543-6.

Full text

Abstract:

Summary At the 2019 ASCO (American Society of Clinical Oncology) Annual Meeting, several interesting trial results were presented in the field of HER2-positive metastatic breast cancer. The end-of-study analysis of the pivotal CLEOPATRA trial indicated an overall survival of 57.1 months in patients receiving pertuzumab in addition to trastuzumab and docetaxel in the first-line setting. SOPHIA was the first phase III trial comparing the Fc-engineered antibody margetuximab plus chemotherapy by physician’s choice with trastuzumab plus chemotherapy in heavily pretreated patients; the novel antibody yielded a statistically significant albeit short prolongation of progression-free survival (PFS) over standard treatment. The phase III NALA trial compared the second-generation tyrosine-kinase inhibitors neratinib with lapatinib; both drugs were combined with capecitabine. In this study a clinically meaningful prolongation of PFS by 2.2 months was observed. In addition, the time to intervention for brain metastases was prolonged in the neratinib group and the cumulative incidence of brain metastases was lower as well. On the downside a high rate of grade 2 and 3 diarrhoea was observed.

APA, Harvard, Vancouver, ISO, and other styles

17

Baselga, José, Javier Cortes, Seock-Ah Im, Xavier B. Pivot, Emma Clark, Adam Knott, Graham Ross, and Sandra M. Swain. "Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 597. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.597.

Full text

Abstract:

597^ Background: In CLEOPATRA, the HER2-dimerization inhibitor pertuzumab (P) was combined with trastuzumab (T) and docetaxel (D) in HER2-positive 1st-line MBC. P+T+D significantly improved efficacy compared with placebo (Pla)+T+D while having little effect on safety. Pts were recommended to receive ≥6 cycles of D but could discontinue D prior to Cycle 6 due to poor tolerability or progressive disease (PD) or continue D beyond Cycle 6 at investigators’ discretion. Once D was discontinued, pts received Pla+T or P+T until PD. To understand the full safety profile of the regimen, adverse events (AEs) occurring before and after D discontinuation were analyzed. Methods: Treatment was given q3w (Pla/P: 840 mg loading, then 420 mg; T: 8 mg/kg loading, then 6 mg/kg; D: 75 mg/m2, escalating to 100 mg/m2 if tolerated; de-escalation by 25% allowed). AEs were graded according to NCI-CTCAE v3.0, monitored continuously during the treatment period, and their relationship to study drugs was assessed by investigators. Results: From 808 pts enrolled, 804 were analyzed in the safety population (pts who received ≥1 dose of study treatment). AEs that led to discontinuation of all study treatment were experienced by 5.3% (Pla+T+D) and 6.1% (P+T+D) of pts, whereas discontinuation of D alone due to AEs occurred in 23.2% (Pla+T+D) and 23.6% (P+T+D) of pts. Conclusions: Treatment in both arms was well tolerated. After discontinuation of D, there was a clear reduction in grade ≥3 AEs; however, the incidence of grade ≥3 diarrhea remained slightly elevated with P+T+D. The AE profile of P+T is consistent with that seen in previous Phase II studies (Gianni Lancet Oncol 2012; Baselga JCO 2010). These data suggest that the combination of P+T may also be well tolerated in other breast cancer settings, such as in adjuvant therapy, which is currently under phase III study (APHINITY; NCT01358877). [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

18

Sivaprasad, Sobha, Joana Vasconcelos, Helen Holmes, Caroline Murphy, Joanna Kelly, Philip Hykin, and Andrew Toby Prevost. "Lightmasks that prevent dark adaptation for non-central diabetic macular oedema: the CLEOPATRA RCT." Efficacy and Mechanism Evaluation 6, no. 2 (February 2019): 1–78. http://dx.doi.org/10.3310/eme06020.

Full text

Abstract:

Background Hypoxia may contribute to the development and progression of diabetic macular oedema (DMO) and diabetic retinopathy. The photoreceptors are the most metabolically active cells in the retina and the rod photoreceptors consume the maximal amount of oxygen for dark adaptation. Therefore, a lightmask emitting 500- to 505-nm light and worn at night during sleep may prevent rod-related dark adaptation and, thereby, reduce the retinal oxygen consumption and improve or prevent progression of DMO and diabetic retinopathy as evidenced in small short-term studies. Objectives The clinical effectiveness and safety of using a lightmask to prevent dark adaptation as a treatment and preventative option was evaluated for DMO over 24 months. Design A Phase III, multicentre, prospective, single-masked, randomised controlled clinical trial that evaluated the clinical effectiveness and safety of a lightmask that prevents dark adaptation to treat and prevent non-central DMO versus standard care (i.e. non-lightmask arm) at 24 months. A subset of participants also enrolled for a mechanistic substudy that evaluated the role of hypoxia in DMO. Setting Fifteen NHS clinical sites in the UK. Participants Adults with non-centre-involving DMO. Intervention The participants were randomly assigned (1 : 1) to being offered a lightmask (Noctura 400 Sleep Masks, Polyphotonix Medical Ltd, Durham, UK) to wear at night during sleep to prevent dark adaptation or to the non-lightmask arm (standard care) for 24 months. The participants were evaluated every 4 months. Main outcome measure The primary outcome was defined as a change in retinal thickness at the zone of maximum thickness measured by spectral domain optical coherence tomography at 24 months in the study eye, analysed using a linear mixed-effects model that estimated adjusted treatment effects at both 12 and 24 months. Results A total of 308 participants were recruited between April 2014 and May 2015. A total of 155 participants in the lightmask arm and 153 in the control arm contributed to the intention-to-treat strategy. The lightmask arm did not show any difference in effect compared with the non-lightmask arm [adjusted mean difference between arms –0.65 µm, 95% confidence interval –6.90 to 5.59 µm; p = 0.84). The compliance of wearing the lightmask was suboptimal, as recorded electronically, from the returned lightmasks. There were no lightmask-related severe adverse events. The mechanistic study aimed at studying the effect of improving hypoxia by inhaling 100% oxygen or by offering lightmasks to wear during sleep at night over 12 months did not demonstrate any clinically beneficial effect on DMO. Conclusion The lightmask, as offered in this trial to prevent dark adaptation, did not show any treatment or preventative effect in participants with non-central oedema or diabetic retinopathy at 24 months. No effect was seen as early as 4 months when compliance was higher. Future work Future research is needed to evaluate the role of rod-induced hypoxia in the pathogenesis of DMO and diabetic retinopathy. Trial registration Current Controlled Trials ISRCTN85596558. Funding This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership. The report will be published in full in Efficacy and Mechanism Evaluation; Vol. 6, No. 2. See the NIHR Journals Library website for further project information. The lightmasks were purchased at a discounted rate from Polyphotonix Medical Ltd.

APA, Harvard, Vancouver, ISO, and other styles

19

Cortés, J., J. Baselga, Y. H. Im, S. A. Im, X. Pivot, G. Ross, E. Clark, A. Knott, and S. M. Swain. "Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer." Annals of Oncology 24, no. 10 (October 2013): 2630–35. http://dx.doi.org/10.1093/annonc/mdt274.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Datko, Farrah Mikhail, Gabriella D'Andrea, Maura N. Dickler, Maria Theodoulou, Shari Beth Goldfarb, Diana Lake, Monica Nancy Fornier, et al. "Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)." Journal of Clinical Oncology 30, no. 27_suppl (September 20, 2012): 134. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.134.

Full text

Abstract:

134 Background: Pertuzumab (P) is a monoclonal antibody which binds to extracellular domain II of HER2 distally from trastuzumab (H), disrupting HER2 dimerization and signaling. The CLEOPATRA phase III trial showed that HP + docetaxel in HER2+ MBC prolonged progression-free survival (PFS) compared to placebo + H + docetaxel. We report preliminary results of a phase II study to evaluate the safety and efficacy of weekly paclitaxel (T) with HP (THP). Methods: Patients (pts) with HER2+ MBC with 0-1 prior treatment (Rx) are eligible. Pts receive weekly (w) paclitaxel (80mg/m2), q3w trastuzumab (loading dose 8mg/kg → 6mg/kg), and q3w pertuzumab (flat loading dose 840mg → flat dose 420mg). The primary endpoint is PFS at 6 months (mo). Secondary endpoints include response, safety (including cardiac events), and tolerability. Evaluable pts are those who have started study Rx and are assessed at 6 mo for PFS. Left ventricular ejection fraction (LVEF) is monitored by echocardiogram every 3 mo. Cardiac events are defined as symptomatic LV systolic dysfunction (LVSD), non-LVSD cardiac death, or probable cardiac death. Results: As of 5-1-12, 33 of the planned 69 pts were enrolled; 16 were evaluable at 6 mo. Of the 16 pts, G 3/4 toxicities included sepsis (1pt, 6%), cholecystitis (1pt, 6%), fatigue (1pt, 6%), skin ulceration (1pt, 6%) and cystic macular degeneration (1 pt with prior prolonged Rx with paclitaxel, 6%). G 1/2 toxicities included alopecia (16 pts, 100%), fatigue (15 pts, 94%), ALT/AST elevation (14 pts, 88%), neuropathy (14 pts, 88%), diarrhea (12 pts, 75%), rash (9 pts, 56%), nail changes (8 pts, 50%), nausea (7 pts, 44%), mucositis (7 pts, 44%), and dry skin (6 pts, 38%). Median LVEF was 63% at baseline, 60% at 3 mo and 58% at 6 mo. There were no cardiac events. At 6 mo, 12/16 pts (75%) were progression-free (2 CR, 7 PR and 3 SD); 4 pts progressed. Conclusions: Our single-center phase II study continues to accrue, with no significant diarrhea or signal of increased cardiac toxicity to date. If the estimate of activity is similar to results with docetaxel in CLEOPATRA, this will provide support for THP as an alternative option in this setting.

APA, Harvard, Vancouver, ISO, and other styles

21

Garrone, Ornella, Chiara Saggia, Alessandra Beano, Federica Cicchiello, Andrea Milani, Ilaria Bertolini, Luigi Coltelli, et al. "From the CLEOPATRA study to real life: An observational study from 11 Italian Centres; Preliminary report from the G.O.N.O. SUPER trial." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e12510-e12510. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e12510.

Full text

Abstract:

e12510 Background: Approximately 20% of breast cancers (BC) are HER-2+. Trastuzumab (T) has substantially improved the outcome, both in early and in advanced settings, in HER-2+BC. Pertuzumab (P), combined with T and taxanes, ameliorated progression free survival (PFS) and overall survival (OS) in the phase III CLEOPATRA study. In order to verify the results of the trial in unselected patients (pts), we performed a multicenter, retrospective-prospective, observational study, in HER-2+ metastatic BC (MBC) pts. Methods: We analyze the outcome of all HER-2+ MBC pts treated with P+T and taxanes, as first line therapy since the availability of P in Italy, at 11 general and university hospitals. Results: Up to February 1stdata from 103 HER-2+ MBC pts were recorded. Main pts’ characteristics were: median (M) age 52 y (28-78), m ECOG PS 0 (0-2), ER/PgR positive 68 pts (66%). Most common metastatic sites: liver 51 pts (49.5%), bone 64 pts (62.1%), lung 26 pts (25.2%). Thirty pts (29.1%) had bone and soft tissue disease only; 78 pts (75.7%) had metastatic disease on presentation. m number of metastatic sites was 3 (1-7); 25 pts (24.3%) received neo/adjuvant chemotherapy (CT) + T and 36 pts (34.9%) adjuvant endocrine therapy; 71 pts (69%) and 32 pts (31%) received docetaxel (D) and paclitaxel (P) respectively. m number of CT cycles was 6 for both drugs (D range 3-12; P range 1-18).At the time of the present analysis 12 pts are still on CT and 78 on maintenance; response is available for 91 pts and ORR is 80.2% (22 pts and 51 pts obtained CR and PR respectively), 6 pts experienced PD during CT. Median PFS is 13.9 months (1.5+ - 33.8+).Among hematological toxicities leucopenia (any grade) was recorded in 29 pts (28.1%), g 3 febrile neutropenia in 6 pts (5.8%). No change of left ventricular ejection fraction (LVEF) was recorded during CT; 4 pts interrupted maintenance P due to drop in LVEF and 1 due to rash. Onicopathy, nausea, alopecia, rash and arthro-myalgia were the most common non-hematological toxicities. Conclusions: Our preliminary results highlight the activity and the safety of the combination of CT plus P and T in unselected HER2+ MBC patients. The study is ongoing and updated results will be presented.

APA, Harvard, Vancouver, ISO, and other styles

22

Swain, Sandra M., Michael S. Ewer, Javier Cortés, Dino Amadori, David Miles, Adam Knott, Emma Clark, Mark C. Benyunes, Graham Ross, and José Baselga. "Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2‐Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study." Oncologist 18, no. 3 (March 2013): 257–64. http://dx.doi.org/10.1634/theoncologist.2012-0448.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Cortes, J., S. Swain, I. Kudaba, M. Hauschild, T. Patel, E. Grincuka, N. Masuda, V. McNally, J. Visich, and J. Baselga. "Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra." Annals of Oncology 23 (September 2012): ix124—ix125. http://dx.doi.org/10.1016/s0923-7534(20)32905-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ribeiro, Rafael Vasconcelos, Glauco de Souza Rolim, Fernando Alves de Azevedo, and Eduardo Caruso Machado. "'Valencia' sweet orange tree flowering evaluation under field conditions." Scientia Agricola 65, no. 4 (2008): 389–96. http://dx.doi.org/10.1590/s0103-90162008000400010.

Full text

Abstract:

Since citrus flowering is a key process in citriculture and its evaluation is often difficult due to the canopy structure and field sampling, the aim of this research was to give some directions regarding the evaluation of flowering in field-grown sweet orange plants. This study was conducted in a citrus orchard of sweet orange plants cv. 'Valencia' [Citrus sinensis (L.) Osbeck] grafted on 'Cleopatra' mandarin (Citrus reshni hort. ex Tanaka) or 'Rangpur' lime (Citrus limonia Osbeck) rootstocks, with North-South orientation. Generative structures [buds, flowers and fruitlets (diameter < 3 cm)] were quantified weekly between August and November 2005, by using a 1 m² frame positioned at the middle third of plant canopy, sampling a volume of about 1 m³. Frames were divided in two parts so that two people could take measurements, and were positioned at Southeast, Southwest, Northeast and Northwest orientations, using seven plants. The following flowering parameters were: (i) number of plants necessary for a representative evaluation of flowering; (ii) plant canopy position to be sampled, and (iii) volume to be evaluated. When considering practical aspects of crop production, a rapid, simple and representative method for flowering evaluation is necessary, especially for growers that frequently have to make strategic decisions about the management of citrus groves. The flowering of field-grown 'Valencia' sweet orange plants can be rapidly assessed by considering at least five plants and sampling canopy volumes of 0.5 m³ in at least one canopy position on each side of the plant row.

APA, Harvard, Vancouver, ISO, and other styles

25

Swain, S. M., J. Baselga, D. Miles, Y. H. Im, C. Quah, L. F. Lee, and J. Cortés. "Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA." Annals of Oncology 25, no. 6 (June 2014): 1116–21. http://dx.doi.org/10.1093/annonc/mdu133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Miles, David, José Baselga, Dino Amadori, Patrapim Sunpaweravong, Vladimir Semiglazov, Adam Knott, Emma Clark, Graham Ross, and Sandra M. Swain. "Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)." Breast Cancer Research and Treatment 142, no. 1 (October 16, 2013): 89–99. http://dx.doi.org/10.1007/s10549-013-2710-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Swain, Sandra M., Young‐Hyuck Im, Seock‐Ah Im, Valorie Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, and José Baselga. "Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA." Oncologist 19, no. 7 (May 28, 2014): 693–701. http://dx.doi.org/10.1634/theoncologist.2014-0033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Miles, David, Andrea Lacasia, Luen Lee, Kenneth Dana, Sarah Heeson, Adam Knott, Chia C. Portera, and Sandra M. Swain. "Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel." Journal of Clinical Oncology 33, no. 15_suppl (May 20, 2015): 598. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.598.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Swain, Sandra M., David Miles, Sung-Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, et al. "End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 1020. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1020.

Full text

Abstract:

1020 Background: Progression-free and overall survival (PFS and OS) were significantly improved with 1L P + H + D v Pla + H + D in 808 pts with HER2-positive MBC in CLEOPATRA (NCT00567190). OS was increased by an unprecedented 15.7 mo (median 56.5 mo with P + H + D v 40.8 mo with Pla + H + D; HR 0.68; 95% CI 0.56, 0.84; p < .001) with a median follow-up of 50 mo [Swain et al. NEJM 2015]). Here we report the end-of-study analysis with a median follow-up of 99 mo (max 120 mo). Methods: In this descriptive analysis, OS was compared between arms using the log-rank test, stratified by prior treatment status and geographic region. The Kaplan–Meier approach was used to estimate median OS, and a stratified Cox proportional hazards model was used to estimate the HR and 95% CIs. Subgroup analyses of OS were performed for stratification factors and other baseline characteristics. Results: Clinical cutoff was Nov 23, 2018. Since Jul 2012, 50 pts crossed from the Pla to the P arm. These pts are counted in the Pla arm for efficacy analyses and up to the first dose of P for safety analyses. The OS HR was 0.69 (95% CI 0.58, 0.82), favoring P + H + D. Median OS was 57.1 mo in the P arm (402 pts) and 40.8 mo in the Pla arm (406 pts; Δ 16.3 mo). The 8-year landmark OS rates were 37% and 23%, respectively. The OS benefit in predefined subgroups, including in pts previously treated with H in the (neo)adjuvant setting (88 pts, HR 0.86; 95% CI 0.51, 1.43), remained consistent with the overall result and previous reports. The overall safety profile of P + H + D was consistent with the known P safety profile. There was only one new serious adverse event suggestive of congestive heart failure (onset ~77 mo on treatment in the P arm, resolution in 34 days, pt continued on study medication) and one new symptomatic left ventricular systolic dysfunction (onset ~46 mo after crossing to the P arm, resolution in 34 days) since the previous analysis. Conclusions: The OS improvement with 1L P + H + D v Pla + H + D for pts with HER2-positive MBC was maintained after an additional 4 years of long-term follow-up, as were the safety and cardiac safety profiles. Clinical trial information: NCT00567190.

APA, Harvard, Vancouver, ISO, and other styles

30

Williams, Carolyn D., William T. Liston, William T. Liston, William T. Liston, Peter J. Smith, Peter J. Smith, Greg Walker, et al. "Reviews Plays: The Jew of Malta, Julius Caesar, Much Ado about Nothing, The Winter's Tale, Hamlet, Henry V, Richard III, Shakespeare's Villains: A Masterclass in Evil, Antony and Cleopatra, Gallathea, La nuit des Rois, Peine d'amour perdue, Roméo et Juliette." Cahiers Élisabéthains: A Journal of English Renaissance Studies 55, no. 1 (April 1999): 75–106. http://dx.doi.org/10.7227/ce.55.1.9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Smith, Peter J., Harry Fox Davies, Laura Campbell, Derek Dunne, Peter J. Smith, Peter J. Smith, Stéphane Huet, et al. "Play Reviews: Henry V, Coriolan/Us, Macbeth, the Tragedie of Cleopatra, Richard III, the Two Gentlemen of Verona, Twelfth Night, Roméo et Juliette [Romeo and Juliet], Macbeth, Two Gentlemen of Verona, the Winter's Tale, Hamlet, Romeo and Juliet, Julius Caesar." Cahiers Élisabéthains: A Journal of English Renaissance Studies 83, no. 1 (April 2013): 33–63. http://dx.doi.org/10.7227/ce.83.1.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Muzhychuk, O. V., and N. V. Bezdetko. "Pharmacoeconomic analysis of pertuzumab in treatment of HER2-positive breast cancer in Ukraine." Український радіологічний та онкологічний журнал 29, no. 1 (March 29, 2021): 21–31. http://dx.doi.org/10.46879/ukroj.1.2021.21-31.

Full text

Abstract:

Background. The incidence of breast cancer tends to be increasing worldwide in recent years. It is characterized by various clinical manifestations and potential treatment approaches. The choice of treatment strategy, its sequence as well as the efficiency of administered chemotherapy is quite relevant these days. Purpose – assessing economic feasibility of targeted therapy with pertuzumab (Perjeta®) in patients with metastatic HER2+ BC from the perspective of the health care system of Ukraine. Materials and methods. The treatment outcomes as well as related costs were determined by means of Markov analytical modelling based on a randomized multicenter open clinical study of CLEOPATRA phase III [2]. The model time horizon was 20 years. The alternative schemes of frontline therapy of metastatic HER2+ breast cancer were compared: PTD regimen pertuzumab + trastuzumab + docetaxel and TD regimen trastuzumab + docetaxel. Based on Markov modelling, pharmacoeconomic analysis by means of cost-effectiveness and cost-utility methods was carried out. As an efficiency criterion, LYG amount was used, as a utility criterion − QALY indicator. Direct medical costs were counted, the structure of which had been determined according to the current Protocol. The cost of drugs was calculated in accordance with the Register of wholesale prices for pharmaceuticals of the Ministry of Health of Ukraine; the cost of treatment procedures was determined in accordance with the available price lists of paid medical services provided by licensed medical institutions. Discounting at the level of 3 % per year was applied. Sensitivity analysis of the outcomes was carried out before pertuzumab price changed. Results. According to the modelling, the average life expectancy of patients with HER2+ BC, receiving PTD scheme is 15.69 years compared to 13.95 years in the TD group. Along with prolonging life, associated with PTD scheme, its quality increases. Patients in the TD group gain 7.8 QALY on average, while in the PTD group it is 9.24. The total expenses for the simulated (involved into modeling) study period in the PTD group averaged UAH 1 970 369.6 per patient, in the TD group − UAH 732 517.7. ICER (cost of 1 additional life year) and ICUR (cost of 1 additional qualityadjusted life year) incremental coefficients amounted to UAH 710924.6 and UAH 861175.4 respectively. Conclusions. 1. Pertuzumab target drug is an effective pharmaceutical when administered to patients with metastatic HER2 + breast cancer. 2. The frontline therapy regimen for patients with metastatic HER2 + breast cancer with pertuzumab being included is more expensive in comparison with trastuzumab + docetaxel regimen; at the same time it makes it possible to achieve better results, i. e. to provide on average extra 1.74 life years and 1.44 QALY in 20-year perspective. 3. Pharmacoeconomic analysis based on Markov model and cost-effectiveness and cost-benefit calculations make it possible to consider pertuzumab (Perjeta®), included into frontline targeted therapy regimen of trastuzumab + docetaxel in patients with metastatic HER2+ breast cancer, as an economically feasible medical technology under current health care conditions in Ukraine.

APA, Harvard, Vancouver, ISO, and other styles

33

Edmondson, Paul, Greg Walker, Greg Walker, Peter J. Smith, Greg Walker, Héloïse Sénéchal, Peter J. Smith, et al. "Reviews Plays: Richard III, a Midsummer Night's Dream, Edward III, Much Ado About Nothing, Antony and Cleopatra, The Tempest, Eastward Ho!, The Island Princess, Twelfth Night, a Midsummer Night's Dream, Henry VI: Revenge in France, Henry VI: Revolt in England, Othello, Titus Andronicus, King Lear, Macbeth, The Alchemist, a Midsummer Night's Dream, La Tempête, Le Conte d'hiver, Juliette et Roméo, Le Songe d'une nuit d'été, Un Volpone, Macbeth, Macbeth." Cahiers Élisabéthains: A Journal of English Renaissance Studies 62, no. 1 (October 2002): 73–142. http://dx.doi.org/10.7227/ce.62.1.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Smith, Peter J., Peter J. Smith, Peter J. Smith, Peter J. Smith, Peter J. Smith, Lisa Hopkins, Jill Pearce, et al. "Reviews Plays: Troilus and Cressida, The Winter's Tale, Othello, a Midsummer Night's Dream, Volpone, Antony and Cleopatra, Twelfth Night, Macbeth, Twelfth Night, The White Devil, The Tempest, Hamlet, The Winter's Tale, The Comedy of Errors, Julius Caesar, Twelfth Night, The Winter's Tale, Vie et Mort du Roi Jean, Le Juif de Malte, York (Henri VI 3e volet—Richard III)." Cahiers Élisabéthains: A Journal of English Renaissance Studies 56, no. 1 (October 1999): 81–117. http://dx.doi.org/10.7227/ce.56.1.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Prescott, Paul, Paul Prescott, Peter J. Smith, Greg Walker, Greg Walker, Peter J. Smith, Jean-Pierre Villquin, et al. "Play Reviews: The Roman Actor, Pericles, The Malcontent, The Merry Wives of Windsor, King Lear, Eastward Ho! As You like it, Measure for Measure Malaya, The Tempest, The Tempest, Othello, Antony and Cleopatra, Beaucoup de bruit pour rien, Richard III, La Tragédie d'Hamlet, Le Songe d'une nuit d'été, Le songe d'une nuit d'été, Falstaff, Le Songe d'une nuit d'été." Cahiers Élisabéthains: A Journal of English Renaissance Studies 63, no. 1 (April 2003): 89–133. http://dx.doi.org/10.7227/ce.63.1.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Smith, Peter J., Greg Walker, Peter Malin, David W. Hartwig, Yvette K. Khoury, Jami Rogers, Will Sharpe, et al. "Play Reviews: The Canterbury Tales, Women Beware Women, Sejanus: His Fall, ‘Tis Pity She's a Whore, ‘Tis Pity She's a Whore, Twelfth Night, the Changeling, Hamlet, Le Roi Lear [King Lear], Antoine et Cléopâtre [Antony and Cleopatra], La Rose et la hache [The Rose and the Axe], Hamlet (un songe) [Hamlet (A Dream)], Richard III, Roméo et Juliette [Romeo and Juliet], Mesure pour mesure [Measure for Measure], Dommage qu'elle soit une putain [‘Tis Pity She's a Whore], Thomas More, un homme pour l'éternité [A Man for All Seasons], Périclès, prince de Tyr [Pericles, Prince of Tyre], Antoine et Cléopâtre [Antony and Cleopatra]." Cahiers Élisabéthains: A Journal of English Renaissance Studies 69, no. 1 (May 2006): 53–93. http://dx.doi.org/10.7227/ce.69.1.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Scott, KJ, J. O'Loughlin, B. England, and EA Roberts. "Effects of water rinses after calcium chloride dips, with and without additives, on the control of bitter pit of apples." Australian Journal of Agricultural Research 36, no. 2 (1985): 305. http://dx.doi.org/10.1071/ar9850305.

Full text

Abstract:

Studies on the control of bitter pit in apples after harvest were conducted during two seasons in Tasmania and New Zealand. The cultivars, Cox's Orange Pippin, Sturmer Pippin, Golden Delicious, Delicious and Cleopatra, which are susceptible to bitter pit on overseas markets, were examined. Bitter pit was reduced and calcium content of the fruit increased, by dipping the fruit in calcium chloride solutions (1-3% w/v). The addition of diphenylamine or the non-ionic wetting agent, Agral 60 (ICI Australia), had little effect on the control of bitter pit or on the calcium content of the treated fruit. Rinsing in water even 1 or 2 days after dipping did not significantly increase the incidence of bitter pit or lower the calcium content of the fruit. There was no difference in the incidence of bitter pit between fruit stored at ambient temperature (15-20�C) or at 3-5�C during the interval between dipping and rinsing. Dipping apples in calcium chloride followed, after 1 or more days, by a water rinse may be suitable commercially for reducing bitter pit in a number of cultivars.

APA, Harvard, Vancouver, ISO, and other styles

38

Smith, Peter J., Gaëlle Ginestet, Greg Walker, Peter Malin, Neil Allan, Andy Kesson, Peter J. Smith, et al. "Reviews: Romeo and Juliet, Antony and Cleopatra, Othello, Hamlet, Julius Caesar, Much Ado about Nothing, the Knight's Tale, a Midsummer Night's Dream, Titus Andronicus, I & II Henry IV, I, II & III Henry VI, King John, the Tempest, Love's Labour's Lost, Henry VIII, the Two Gentlemen of Verona, Troilus and Cressida, the Rape of Lucrece, All's Well That Ends Well, Richard III, the Comedy of Errors, Measure for Measure, Cymbeline, Timon of Athens, the Winter's Tale, Hamlet, Pericles, the Taming of the Shrew, the Phoenix and Turtle, Richard II, Merry Wives: The Musical, Richard III, Henry V, Richard III: An Arab Tragedy, Macbeth, Coriolanus, Nothing like the Sun (Sonnets), Twelfth Night, or What You Will, as You like it, Venus and Adonis, the Merchant of Venice, King Lear." Cahiers Élisabéthains: A Journal of English Renaissance Studies 71, no. 1_suppl (May 2007): 29–89. http://dx.doi.org/10.7227/ce.spiss07.1.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Pelling, Christopher. "M. G. Schmidt, Caesar und Cleopatra: Philologischer und historischer Kommentar zu Lucan 10,1–171 (Studien zur klassischen Philologie xxv.) Frankfurt etc.: P. Lang, 1986. Pp. xxii + 258. ISBN 3-8204-8383-7. Sw.fr. 61. - Caesar's War in Alexandria: Bellum Civile III. 102–112 and Bellum Alexandrinum 1–33. Ed. G. Townend. Bristol and Wauconda, Illinois: Bristol Classical Press and Bolchazy-Carducci, 1986. Pp. vi + 66, 1 map. ISBN 1-85399-044-2 (UK), 0-86516-219-0 (USA). £4.95." Journal of Roman Studies 81 (November 1991): 198–99. http://dx.doi.org/10.2307/300517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Lowe, Eleanor, Peter J. Smith, Jeffrey C. Steele, Greg Walker, Peter J. Smith, Eleanor Lowe, Peter J. Smith, et al. "Play Reviews: Measure for Measure, The Taming of the Shrew, Richard III, Edward II, Richard II, The Taming of the Shrew, Dido, Queen of Carthage, a Midsummer Night's Dream, The Bomb-itty of Errors, The Duchess of Malfi, Henry V, Love's Labour's Lost, Pericles, The Winter's Tale, Othello in Black and White, Henry V, a Woman Killed with Kindness, Macbeth, The Taming of the Shrew, Antony and Cleopatra, Pericles, Romeo and Juliet, Le Songe d'une nuit d'été, Hamlet, La Tempête, Le Marchand de Venise, La Nuit des rois, El-Zir Salem et le prince Hamlet." Cahiers Élisabéthains: A Journal of English Renaissance Studies 64, no. 1 (November 2003): 57–100. http://dx.doi.org/10.7227/ce.64.1.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Rossini, Alessandro. "Letters from Ptolemy VIII, Cleopatra II, and Cleopatra III Concerning the Gymnasium of Omboi." Axon, no. 2 (December 12, 2022). http://dx.doi.org/10.30687/axon/2532-6848/2022/02/006.

Full text

Abstract:

In 135 BC, the gymnasium of Omboi (Upper Egypt) issued a decree immortalising on stone the correspondence concerning some philanthropa bestowed by Ptolemy VIII, Cleopatra II, and Cleopatra III. Only a few years later, the dossier was defaced and the royal names were erased (damnatio memoriae) except for that of Cleopatra II. The inscription has thus been interpreted as an epigraphic evidence of the civil war between Ptolemy VIII, flanked by Cleopatra III, and Cleopatra II. In spite of its poor state of preservation, the Omboi dossier allows some useful considerations on its vicissitudes, along with some further restorations.

APA, Harvard, Vancouver, ISO, and other styles

42

Heredia Castillo, Alejandro. "FUENTE PÉREZ, María Jesús y RUIZ FRANCO, Rosario (eds.): Mujeres peligrosas. Madrid, Universidad Carlos III, 2019." Arenal. Revista de historia de las mujeres 27, no. 2 (December 5, 2020). http://dx.doi.org/10.30827/arenal.v27i2.13649.

Full text

Abstract:

El siguiente trabajo conforma una excelente aportación para el estudio de la Historia de las Mujeres, no es sino otro de los muchos trabajos actuales cuya temática está centrada en la valorización de aquellas figuras históricas femeninas que han sido consideradas como “mujeres peligrosas. En este sentido debemos hacer referencia a los estudios de Anthony Barret sobre las emperatrices Livia y Agripina la Menor, Livia, first lady of imperial Rome (2002) y Agrippina: sex, power and politics in the Early Empire (1996), Joyce Tyldesley en relación a la figura de Cleopatra, Cleopatra, la última reina de Egipto (2010) o la publicación de Diana Pelaz López que sigue en esencia la línea temática de la composición a reseñar, las mujeres poderosas como obstáculos políticos para determinados sectores de la élite masculino, Jaque a la reina, cuando la mujer se convierte en un estorbo político (2011)…

APA, Harvard, Vancouver, ISO, and other styles

43

Xu, Binghe, Wei Li, Qingyuan Zhang, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, et al. "Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study." Breast Cancer Research and Treatment, December 4, 2022. http://dx.doi.org/10.1007/s10549-022-06775-1.

Full text

Abstract:

Abstract Purpose PUFFIN (NCT02896855), a Chinese bridging study in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer, assessed consistency of efficacy and safety of pertuzumab plus trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel, with CLEOPATRA (NCT00567190). Methods Eligible patients, n = 243, were randomized 1:1, stratified by visceral disease and hormone receptor status, to pertuzumab, trastuzumab, and docetaxel or placebo, trastuzumab, and docetaxel. Primary endpoint: investigator-assessed progression-free survival (PFS). Secondary endpoints: safety and overall survival (OS). After primary analysis, patients could cross over to the pertuzumab arm. Results Updated median PFS: 16.5 months (pertuzumab arm) and 12.5 months (placebo arm), with a hazard ratio (HR) of 0.60 [95% confidence interval (CI) 0.45, 0.81; p = 0.0008]. Median OS was not reached in either arm; the OS HR was 0.68 (95% CI 0.45, 1.03; p = 0.0658). Safety was similar in both arms with no new safety signals: 73.8% (pertuzumab arm) and 69.2% (placebo arm) experienced grade ≥ 3 adverse events. No heart failure, symptomatic left ventricular systolic dysfunction, or left ventricular ejection fraction decline of < 40% were reported. Conclusions The PUFFIN final analysis showed, per the primary analysis, that overall efficacy of pertuzumab plus trastuzumab and docetaxel was consistent with CLEOPATRA. Safety remained consistent with the known pertuzumab profile. Overall, PUFFIN contributes to the totality of data with pertuzumab in previously untreated HER2-positive locally recurrent or metastatic breast cancer and supports the favorable benefit–risk profile of pertuzumab in Chinese patients. Trial registration: ClinicalTrials.gov, NCT02896855, registered 7 September 2016.

APA, Harvard, Vancouver, ISO, and other styles

44

Rajarajan, R. K. K. "Deathbed, Breathing the Last, and Funeral Procession: Musing under the canopy of history." Chitrolekha Journal on Art and Design 3, no. 1 (June 20, 2019). http://dx.doi.org/10.21659/cjad.31.v3n102.

Full text

Abstract:

“In Nature’s book of infinite secrecy/ A little I can read”. These words of the soothsayer in Shakespeare’s ‘Antony and Cleopatra’ (Act I, Scene ii) is symbolic. It is uttered in the company of Charmian and Iras, maidens attending on Cleopatra (Hutchinson n.d.: pl. facing p. 39); perhaps designed to foretell the end of Mark Antony[i] in the near future after the battle of Actium. Everything existing on this earth must pass through nature to eternity that is denoted by the common word “death”. But, death at a young age is cruel whether natural, volunteered, accidental or due to any injunction. The brilliant Tamil woman-mystic ?????[ii] and the versatile English poet, John Keats[iii] died at a young age that was a great loss to the world of literature. The Buddha as a novice-monk was in pursuit of death but gave up the unnatural process of suicidal mortification (Le-Bon 1974: fig. p. 55, Yiengpruksawan 2007: 44-63, Ahuja 2013: fig. 6, pp. 21-24) and resorted to yoga to realize cosmic realities under the Bodhi tree at S?ran?th (Parimoo et al. 1991: I, pls. 50-45, 106-107)[iv]. Jesus of Nazareth (cf. Gallico 1999: figures on pages 111, 20 & 42, Ahuja 2013: fig. 39) and Mu?ammad of Mecca (cf. Stewart 1980: figures on pages 36-37) died at a relatively young age; otherwise the history of world’s greatest religions would have been different. If they had lived long […]; this “if” factor in history is difficult to answer. Neither Jesus nor Mu?ammad “invited” nor “pursued” death (Settar 1986, 1990); one was crucified by Jewish treachery of those times and other of some other malady. Preachers of terrorism do not die under a peaceful environment. “Whoso sheddeth man’s blood, by man shall his blood be shed for in the image of God made he man” (Genesis 9.6).

APA, Harvard, Vancouver, ISO, and other styles

45

Sobecki, Sebastian. "The Handwriting of Fifteenth-Century Privy Seal and Council Clerks." Review of English Studies, September 2, 2020. http://dx.doi.org/10.1093/res/hgaa050.

Full text

Abstract:

Abstract Although most scholars of medieval English palaeography are familiar with the hand of the Privy Seal clerk and poet Thomas Hoccleve, almost nothing is known about the handwriting of his fellow clerks. This article is the first attempt to identify and describe the hands of a number of clerks who wrote for the Privy Seal and for the Council in the fifteenth century. In Part 1, I identify the handwriting of Hoccleve’s fellow clerks, including William Alberton, Henry Benet, John Claydon, John Hethe, John Offord, and Richard Priour, adding writs, letters, charters, and manuscripts in their hands. I also identify the hand of the Council clerk Richard Caudray and attribute further records to the Council and Privy Seal clerk Robert Frye. Part 2 offers a reconsideration of the features of Hoccleve’s handwriting in the light of the new findings. This article also identifies the scribal stints and hands in four documents produced by Privy Seal clerks: British Library, MS Add. 24,062 (Hoccleve’s Formulary); BL, MS Cotton Cleopatra F. iii (Part 1 of the Book of the Council); BL, MS Harley 219; and Edinburgh University Library, MS 183 (Privy Seal and Signet formulary, or ‘Royal Letter Book’). This article reveals the extent to which Privy Seal clerks participated in the copying of literature and offers a more nuanced understanding of the varieties of the secretary script used by government scribes.

APA, Harvard, Vancouver, ISO, and other styles

46

Jørgensen, Jan Trøst, Henrik Winther, Jon Askaa, Lena Andresen, Dana Olsen, and Jens Mollerup. "A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer." Frontiers in Oncology 11 (July 23, 2021). http://dx.doi.org/10.3389/fonc.2021.676939.

Full text

Abstract:

The development of trastuzumab (Herceptin®) was one of the most significant cancer drug development projects of the 20th century. Not only was it a scientific and medical achievement but it also paved the way for the drug-diagnostic codevelopment model, where a predictive biomarker assay is developed in parallel to the drug. One of the challenges in the development of trastuzumab was to select the right patient population likely to respond and here, it was critical to have access to an accurate, robust and reliable assay for detection of HER2 overexpression in tumors. In the clinical development of trastuzumab, a clinical trial assay (CTA), developed by Genentech, was used for selection of HER2 positive patients. However, during the phase III trial with trastuzumab, a new optimized IHC assay, HercepTest™ was designed and developed by Dako. In the final stage of its development, a comparative study with the CTA was conducted in order to show concordance between the two assays. In September 1998, the Food and Drug Administration (FDA) simultaneously granted approval to trastuzumab and HercepTest™. The assay has been used for patient selection in a number of significant breast cancer clinical trials such as the HERA, CLEOPATRA, EMILIA and more. In these trials, HercepTest™ demonstrated its clinical utility in the neoadjuvant, adjuvant, and metastatic setting as well as in relation to different types of HER2 targeted therapies. Likewise, the assay was used for selection of HER2 positive gastric cancer patients in the important ToGA trail. HercepTest™ was the first companion diagnostic ever approved by the FDA, and more than 20 years of use has documented its clinical impact.

APA, Harvard, Vancouver, ISO, and other styles

47

Sivaprasad, Sobha, Geoffrey Arden, A. Toby Prevost, Roxanne Crosby-Nwaobi, Helen Holmes, Joanna Kelly, Caroline Murphy, Gary Rubin, Joanna Vasconcelos, and Philip Hykin. "A multicentre phase III randomised controlled single-masked clinical trial evaluating the cl inical e fficacy and safety o f light-masks at p reventing dark-a daptation in the tr eatment of ea rly diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial." Trials 15, no. 1 (November 22, 2014). http://dx.doi.org/10.1186/1745-6215-15-458.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!